Why Multi-Site Studies Matter   Physiological monitoring devices increasingly rely on clinical evidence that reflects real-world use and diverse populations. Some studies may require clinical data to be collected across multiple research locations. Multi-site clinical research studies allow sponsors to expand recruitment and collect larger datasets while maintaining consistent study protocols. When executed under Good Clinical Practice (GCP) and ISO 14155, multi-site program

As wearable and software-enabled technologies increasingly estimate physiological parameters such as oxygen saturation, blood pressure, and heart rate variability, regulatory classification has become a critical design consideration. The FDA’s General Wellness: Policy for Low Risk Devices clarifies when products using non-invasive sensing—such as optical sensing—may be considered general wellness products rather than regulated medical devices.  For developers conducting a cl

In clinical research for medical devices and wearable technologies, data quality is everything . Regulatory clearance depends not just on whether a study was conducted, but on whether the data generated is regulator-ready, reproducible, and scientifically defensible . Yet not all Service Providers (formally known as Clinical Research Organizations (CROs)) bring the same level of expertise, infrastructure, or dedicated staff to ensure that outcome.  Sponsors sometimes face a d

For medical device and wearable technology developers, the success of a clinical research study often hinges on one factor: the quality of the data. High-quality, regulator-ready data not only supports FDA or CE mark submissions but also reduces the risk of costly delays and resubmissions. One of the most effective ways to secure reliable study outcomes is by partnering with a Contract Research Organization (CRO) —particularly one based in the United States.  Why Location Mat

When preparing for a regulatory-grade validation study, the temptation is often to move quickly into execution. However, a carefully designed pilot study can reduce risk of costly setbacks such as protocol deviations, recruitment challenges, and misaligned endpoints. Pilot studies act as a proving ground—helping refine study design, anticipate risks, and improve the quality of the data that will ultimately support regulatory submissions.  Defining the Role of a Pilot Study  

When developing a new medical device or wearable technology, navigating the FDA regulatory pathway can be complex and resource-intensive. One of the most effective tools available to device developers is the FDA Q-Submission (Q-Sub) process . This process allows sponsors to engage the FDA early, gain clarity on requirements, and ultimately reduce the risk of costly delays in bringing innovations to market.    What is an FDA Q-Submission?   An FDA Q-submission is a way for dev

PRL research staff performing synchronized data collection at multiple sites to ensure consistent, FDA-compliant results. Why Multi-Site Studies Matter for FDA Submissions   Multi-site clinical research studies are often a necessity for medical device and wearable technology developers seeking FDA clearance. They enable broader participant diversity, increase enrollment speed, and strengthen the statistical power of results.  However, multi-site execution introduces complex r

Sponsors often choose CROs based on price or speed, but the wrong partner can cost far more. Delayed timelines. Poor data. FDA...